Home > Insider Trading > Filing (0001104659-16-131584)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1556263	Syros Pharmaceuticals Inc.	SYRS	Pharmaceutical Preparations (2834)	453772460

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1611189	Polaris Partners Vii, L.p.	One Marina Park Drive, 10Th Floor Boston MA 02210	No	No	Yes	No
1615991	Polaris Entrepreneurs' Fund Vii, L.p.	One Marina Park Drive, 10Th Floor Boston MA 02210	No	No	Yes	No
1678203	Polaris Management Co. Vii, L.l.c.	One Marina Park Drive, 10Th Floor Boston MA 02210	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-07-06	1,164,486	$0.00	1,164,486	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2016-07-06	22,167	$0.00	22,167	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2016-07-06	373,847	$12.50	1,538,333	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2016-07-06	26,153	$12.50	48,320	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2016-07-06	4,366,825	$0.00	1,164,486	$0.00
Common Stock	Series B Preferred Stock	Disposition	2016-07-06	83,129	$0.00	22,167	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

The Series B Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The reportable securities are owned directly by Polaris Partners VII, L.P. ("PP VII"). Polaris Management Co. VII, L.L.C. ("PMC VII") is the general partner of PP VII. PMC VII disclaims beneficial ownership of these securities and this report shall not be deemed an admission that PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of its pecuniary interest therein.
The reportable securities are owned directly by Polaris Entrepreneurs' Fund VII, L.P. ("PEF VII"). PMC VII is the general partner of PEF VII. PMC VII disclaims beneficial ownership of these securities and this report shall not be deemed an admission that PMC VII is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of its pecuniary interest therein.